

ALLIA.143CP3



PATENT

7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Habib Zaghouani ) Group Art Unit 1644  
App. No. : 09/873,901 )  
Filed : June 4, 2001 )  
For : COUPLING OF PERIPHERAL )  
TOLERANCE TO ENDOGENOUS )  
IL-10 PROMOTES EFFECTIVE )  
MODULATION OF T CELLS AND )  
AMELIORATES AUTOIMMUNE )  
DISEASE )  
Examiner : Unknown )

RECEIVED  
FEB 11 2002  
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing fifteen (15) references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Jan 22, 2002


By: Daniel Hart

Daniel Hart  
Registration No. 40,637  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ALLIA.143CP3APPLICATION NO.  
09/873,901INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Habib ZaghouaniFILING DATE  
June 4, 2001GROUP  
1644

RECEIVED  
FEB 11 2002  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,969,109	10/19/99	Bona, et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	2	WO 96/19584	06/27/96	PCT				
	3	WO 99/09064	02/25/99	PCT				
	4	WO 00/01732	01/13/00	PCT				

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	5 ✓	Adorini, et al., New Perspectives on Immunointervention in Autoimmune Diseases, Immunol. Today, 11(11):383-386 (1990).
	6 ✓	Cullen, et al., A Divalent Major Histocompatibility Complex/IgG1 Fusion Protein Induces Antigen-specific T Cell Activation <i>in vitro</i> and <i>in vivo</i> , Cellular Immunology 192(1):54-62 (1999).
	7 ✓	Endoh, et al., Studies of Experimental Allergic Encephalomyelitis in Old Mice, J. of Neuroimmunol., 29:21-31 (1990).
	8 ✓	Gosselin, et al., Enhanced Antigen Presentation Using Human Fcγ Receptor (Monocyte/Macrophage)-Specific Immunogens, J. Immunol., 149(11):3477-3481 (1992).
	9 ✓	Muller, et al., Selective <i>in vivo</i> Inhibition of T Cell Activation by Class II MHC-Binding Peptides Administered in Soluble Form, J. Immunol., 145(12):4006-4011 (1990).
	10 ✓	Riechmann, et al., Reshaping human antibodies for therapy, Nature, Vol. 332, March 24: 323-327 (1988).
	11 ✓	Sollazzo, et al., Expression of an exogenous peptide epitope genetically engineered in the variable domain of an immunoglobulin: implications for antibody and peptide folding, Protein Engineering, Vol. 4, No. 2: 215-220 (1990).
	12 ✓	Takemori, et al., Mechanism of Neonatally Induced Idiotype Suppression and its Relevance for the Acquisition of Self-tolerance, Immunological Reviews, 79:103-117.
	13 ✓	Zaghouani, et al., Engineered Immunoglobulin Molecules as Vehicles for T Cell Epitopes, Intern. Rev. Immunol., 10: 265-278 (1993).
	14 ✓	Zaghouani, Habib, U.S. App. No. 10/000,868, filed 11/30/01, entitled "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143DV1.
	15	International Search Report for co-pending Application No. PCT/US01/40834.

S:\DOCS\SGJ\SGJ-1415.DOC:dmb  
012202

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.